Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA von Kaseb, Ahmed O, Sánchez, Nora S, Sen, Shiraj, Kelley, Robin K, Tan, Benjamin, Bocobo, Andrea G, Lim, Kian H, Abdel-Wahab, Reham, Uemura, Marc, Pestana, Roberto Carmagnani, Qiao, Wei, Xiao, Lianchun, Morris, Jeffrey, Amin, Hesham M, Hassan, Manal M, Rashid, Asif, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Mills-Shaw, Kenna R, George, Bhawana, Haque, Abedul, Raghav, Kanwal P S, Wolff, Robert A, Yao, James C, Meric-Bernstam, Funda, Ikeda, Sadakatsu, Kurzrock, Razelle

Volltext

Mouse Cardiac Acyl Coenzyme A Synthetase 1 Deficiency Impairs Fatty Acid Oxidation and Induces Cardiac Hypertrophy von Ellis, Jessica M., Mentock, Shannon M., DePetrillo, Michael A., Koves, Timothy R., Sen, Shiraj, Watkins, Steven M., Muoio, Deborah M., Cline, Gary W., Taegtmeyer, Heinrich, Shulman, Gerald I., Willis, Monte S., Coleman, Rosalind A.

Volltext

Return to the fetal gene program: a suggested metabolic link to gene expression in the heart von Taegtmeyer, Heinrich, Sen, Shiraj, Vela, Deborah

Volltext

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects wi... von Spira, Alexander I, Gordon, Michael S, Henry, Jason, Patel, Sandip P, Sehgal, Kartik, Sen, Shiraj, Sweis, Randy, Crochiere, Marsha, He, Shui, Smyrnios, Sondra, Unadkat, Dipali, Zhang, Bin, Tolcher, Anthony W

Volltext

Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Re-educate Patients on Prognosis? von Moreland, Sarah, Sen, Shiraj

Volltext

Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Reeducate Patients on Prognosis? von Moreland, Sarah, Sen, Shiraj

Volltext

Return to the fetal gene program von Taegtmeyer, Heinrich, Sen, Shiraj, Vela, Deborah

Volltext

Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types von Sen, Shiraj, Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek

Volltext

Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis von Kundu, Bijoy K., Zhong, Min, Sen, Shiraj, Davogustto, Giovanni, Keller, Susanna R., Taegtmeyer, Heinrich

Volltext

Everything Points to Myeloma von Gupta, Arjun, Sen, Shiraj, Pandey, Ambarish

Volltext

Prognostic Factors and Outcomes in Primary Effusion Lymphoma in HIV-Infected Patients: A Single Center Experience von Sen, Shiraj, Marley, Eileen, Naina, Harris V.

Volltext

A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in pati... von Hong, David S., Sen, Shiraj, Park, Haeseong, Heist, Rebecca Suk, Gadgeel, Shirish M., Zimmerman, Zachary Franklin, Bazhenova, Lyudmila

Volltext

Bariatric surgery to unload the stressed heart: a metabolic hypothesis von Algahim, Mohamed F, Sen, Shiraj, Taegtmeyer, Heinrich

Volltext

Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians von Chung, Christine Y., Galvin, Rachael, Achenbach, Ella, Dziadkowiec, Oliwier, Sen, Shiraj

Volltext

Real-world data evaluating immunotherapy markers and checkpoint inhibitor response among GI cancers in a large community-based oncology network von Jones, Carissa, Lachs, Rebecca, Sturgill, Emma, Misch, Amanda, Lietman, Caressa, Jones, Suzanne Fields, Burris III, Howard A., Sen, Shiraj, Bendell, Johanna C.

Volltext

Persistent Intracardiac Thrombus: Could it be Cancer? von Sen, Shiraj, Naina, Harris V., Gupta, Arjun

Volltext

Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose von Sen, Shiraj, Hong, David S., Hess, Kenneth, Meric-Bernstam, Funda, Subbiah, Vivek

Volltext

Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early Phase Clinical Trials von Galvin, Rachael, Chung, Christine, Achenbach, Ella, Dziadkowiec, Oliwier, Sen, Shiraj

Volltext

Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials von Sen, Shiraj, Hess, Kenneth R., Hong, David S., Naing, Aung, Huang, Le, Meric-Bernstam, Funda, Subbiah, Vivek

Volltext

A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors von Borazanci, Erkut Hasan, Janku, Filip, Hamilton, Erika P., Thomas, Jacob Stephen, Sen, Shiraj, Fu, Siqing, Wheeler, Catherine A., Wages, David S., Matsumoto, Takeshi, Shimoyama, Susumu, Yamada, Naoki, Subach, Ruth Ann, Madden, Timothy, Johansen, Mary, Maier, Gary, Cheung, Kin, Korn, Ron, Falchook, Gerald Steven

Volltext